Skip to content Skip to footer
Subscribe Now
NEWS

Algen Biotechnologies Collaborates with AstraZeneca to Advance Drug Discovery in Immunology

Shots: Algen has entered into a multi-target collaboration with AstraZeneca to accelerate novel immunology target discovery, leveraging the AlgenBrain platform As per the deal, AstraZeneca will receive exclusive rights to develop and commercialize therapies for selected targets identified through the partnership in exchange for ~555M incl. upfront, development, regulatory & commercial milestone payments  AlgenBrain models disease…
October 7, 2025

Read more

NEWS

Roche and KlinRisk Secure CE Mark for Kidney Klinrisk Algorithm and Unveil CKD Algorithm Panel

Shots: Roche & KlinRisk have received CE-mark approval for the AI-based Kidney Klinrisk Algorithm to assess progressive kidney function decline, integrated into the navify Algorithm Suite The chronic kidney disease algorithm panel combines the new Klinrisk Algorithm for early risk assessment with the CE-marked KFRE Algorithm for later disease stages, supporting care across the full…
October 6, 2025

Read more

NEWS

Variational AI Collaborates with Merck to Develop Small Molecule Therapeutics

Shots: Variational AI has entered into a collaboration with Merck to design and optimize novel small molecule candidates against two undisclosed targets using Variational AI’s Enki platform As per the deal, Variational AI will leverage its fine-tuned Enki platform trained on Merck’s proprietary data to generate & optimize small-molecule candidates for Merck’s targets, with Merck…
September 24, 2025

Read more

NEWS

SignalPET Launches SignalPET 360° for Comprehensive Veterinary Radiology

Shots: SignalPET has launched SignalPET 360°, an integrated AI-powered radiology solution for veterinary medicine SignalPET 360 provides an integrated diagnostic platform with built-in PACS, allowing clinics to store & view all imaging modalities, generate AI-powered reports for every case, & seamlessly escalate to advanced AI or radiologist review when required SignalPET 360° suite provides immediate…
September 5, 2025

Read more

Shawn Opatka from Honeywell in a Riveting Dialogue Exchange with PharmaShots
VIEWPOINTS

AI-Mediated Recalls: Shawn Opatka from Honeywell in a Riveting Dialogue Exchange with PharmaShots

Shots:  Product recalls in biopharma and MedTech incur an unanticipated drain on budget, costing the industry between $2.5B to $5B per year on average  Honeywell’s TrackWise Recall Management helps biopharma and MedTech companies plan and execute recall processes seamlessly, contributing to improved patient safety and faster response times  Shawn Opatka, Vice President & General Manager,…
September 1, 2025

Read more

Roadblocks to Specialty Medicines Access: Colin Banas from DrFirst in Conversation with PharmaShots
VIEWPOINTS

Roadblocks to Specialty Medicines Access: Colin Banas from DrFirst in Conversation with PharmaShots 

Shots:  Fragmented workflows continue to be a major roadblock in the healthcare ecosystem, causing unnecessary delays in care delivery  Automated solutions help bridge the gaps resulting from disjointed workflows and expedite prior authorization, pharmacy routing, and patient onboarding  Colin Banas, CMO at DrFirst, joins PharmaShots in a discussion highlighting the company’s recent acquisition of Myndshft…
August 20, 2025

Read more

Pharmaceutical Automation and Digitalisation Congress (AUTOMA+) 2025
EVENTS

Pharmaceutical Automation and Digitalisation Congress (AUTOMA+) 2025 

The Pharmaceutical Automation and Digitalisation Congress (AUTOMA+) 2025 takes place in Vösendorf, Austria on 24-25 November. The 5th anniversary edition of AUTOMA+ gathers leading innovators and IT professionals to discuss the directions of the advanced industry shift and celebrate this milestone together.   The 2-day agenda includes topics:  Ethical and human-centric AI;  Smart manufacturing techniques (digital…
August 18, 2025

Read more

NEWS

DoveTree Medicines Enters a ~$5.99B Deal with XtalPi to Discover Novel Therapeutics Across Various Indications

Shots: XtalPi has entered into a strategic collaboration with DoveTree Medicines to identify novel therapeutics across oncology, immunology, inflammation, neurology, & metabolic diseases, leveraging XtalPi's de novo drug discovery platform As per the deal, DoveTree will gain exclusive global rights to develop & commercialize multiple therapeutics from the collaboration, in exchange for a $51M upfront,…
August 8, 2025

Read more

Load more